Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Hemispherx Biopharma, Inc. (HEB) Starts Presentation at 2015 Marcum MicroCap Conference

Hemispherx Biopharma is engaged in the manufacture and clinical development of new drug entities for the treatment of seriously debilitating disorders especially life-threatening viruses. The company’s flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including chronic fatigue syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. For more information, visit the company’s website at www.hemispherx.net.

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.